These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23515408)

  • 1. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
    Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
    Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
    Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
    Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
    Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
    Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
    Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
    Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
    Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
    Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
    Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
    Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
    Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
    Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
    Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
    Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
    Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
    Opel D; Schnaiter A; Dodier D; Jovanovic M; Gerhardinger A; Idler I; Mertens D; Bullinger L; Stilgenbauer S; Fulda S
    Int J Cancer; 2015 Dec; 137(12):2959-70. PubMed ID: 26096065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.
    Jantus-Lewintre E; Sarsotti E; Terol MJ; Benet I; García-Conde J
    Clin Transl Oncol; 2006 Nov; 8(11):805-11. PubMed ID: 17134969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
    Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
    Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.
    Campàs C; Lopez JM; Santidrián AF; Barragán M; Bellosillo B; Colomer D; Gil J
    Blood; 2003 May; 101(9):3674-80. PubMed ID: 12522004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.